

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Mazer Ally, MD	Speaker	<ul style="list-style-type: none"> AbbVie Lilly, Sanare 	<ul style="list-style-type: none"> Speaker Consultant
Lori Beeken, MS, RDN	Speaker, Planning Committee	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Brigid Boland, MD	Speaker, Planning Committee	<ul style="list-style-type: none"> Merck, Mirador Gilead, Prometheus Labs Pfizer 	<ul style="list-style-type: none"> Research grant, consultant Research grant Consultant
Angelina Collins, MSN, ANP-BC	Speaker, Planning Committee	<ul style="list-style-type: none"> AbbVie, Janssen Eli Lilly Takeda 	<ul style="list-style-type: none"> Speaking, Consulting, Advisory Board Speaking, Advisory Board Speaking, Consulting
Melissa Ferrari, PA-C	Speaker, Planning Committee	<ul style="list-style-type: none"> AbbVie BMS 	<ul style="list-style-type: none"> Speaker Consultant
Robert Goldklang, MD	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Sara Horst, MD	Speaker	<ul style="list-style-type: none"> AbbVie, BMS, Janssen, Pfizer, Takeda 	<ul style="list-style-type: none"> Consultant
Vipul Jairath, MBChB	Speaker	<ul style="list-style-type: none"> AbbVie, Alimentiv, Altrubio, Amgen, AnaptysBio, Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Avoro Capital, BiomeBank, Boehringer Engelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Endpoint Health, Entera, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, Gilde Healthcare, GlaxoSmithKline, Genentech, Gilead, Innomar, JAMP, Janssen, Merck, Metacrine, MRM Health, Mylan, Organon, Pandion, Pendopharm, Pfizer, Protagonist, Reistone Biopharma, Roche, Roivant, Sandoz, Second Genome, Sorriso, Spyre Therapeutics, Synedgen, 	<ul style="list-style-type: none"> Consulting, Advisory Board Speaker

		Takeda, Teva, TD Cowen Inc, Tillotts, Topivert, Union Therapeutics, Ventyx, Vividion <ul style="list-style-type: none"> Abbvie, Ferring, Bristol Myers Squibb, Galapagos, Janssen Pfizer Shire, Takeda, Fresenius Kabi 	
Melissa Kirkpatrick, PharmD	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Gauree Gupta Konijeti, MD	Speaker, Planning Committee	<ul style="list-style-type: none"> Lilly, Takeda AbbVie, Pfizer 	<ul style="list-style-type: none"> Speaker Advisory Board
Edward Loftus, Jr., MD	Speaker	<ul style="list-style-type: none"> AbbVie, Alvotect, Amgen, Arena, Avalo Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Exact Sciences, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Scopes, Janssen, KSL Diagnostics, Lilly, Morphic, Ono Pharma, Pfizer, Protagonist, Receptos, Robarts Clinical Trials, Scipher Medicine, Sun Pharma, Surrozen, Takeda, Theravance 	<ul style="list-style-type: none"> Not Specified, TBD
Rebecca Matro, MD	Speaker, Planning Committee	<ul style="list-style-type: none"> AbbVie 	<ul style="list-style-type: none"> Speaker
Anne Peery, MD	Speaker	<ul style="list-style-type: none"> dsm-firmenich, Alfasigma 	<ul style="list-style-type: none"> Research Funding
Suresh Pola, MD	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Jenny Sauk, MD	Speaker	<ul style="list-style-type: none"> AbbVie, Prometheus CorEvitas 	<ul style="list-style-type: none"> Speaker's Bureau Consultant
Siddharth Singh, MD	Speaker, Planning Committee	<ul style="list-style-type: none"> Pfizer Pfizer, AbbVie 	<ul style="list-style-type: none"> Grant Fees Research Funding
M. Jonathan Worsey, MD	Speaker, Planning Committee	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
CME Committee	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.